USANA Health Sciences, Inc. Annual report pursuant to Section 13 and 15(d)

Equity-Based Compensation (Tables)

12 Months Ended

Dec. 28, 2013



2014		$ 5,948
2015		4,040
2016		2,085
2017		1,286
2018		236
		$ 13,595

The cost above is expected to be recognized over a weighted-average period of 1.9 years.


	Year Ended
	2011	2012	2013

Expected volatility (1)	56.0%	50.7%	41.9%
Risk-free interest rate (2)	1.1%	0.6%	0.7%
Expected life (3)	3.9 yrs.	3.9 yrs.	3.9 yrs.
Expected dividend yield (4)	0.0%	0.0%	0.0%
Weighted-average grant price (5)	$ 28.89	$ 39.41	$ 53.83

(1) Through June, 2012 expected volatility was a weighted-average of historical volatility and implied volatility.
In July 2012, the Company eliminated the implied volatility aspect of this calculation and began utilizing
historical volatility alone.
(2) Risk-free interest rate is based on the U.S. Treasury yield curve with respect to the expected life of the award.
(3) For awards that follow the 20% per year vesting schedule, expected life is a weighted-average that includes
historical settlement data of the Company's equity awards and a hypothetical holding period for outstanding
awards. Due to lack of historical settlement data on awards that follow the 50% vesting at each of years four
and five, expected life of these awards is calculated under the simplified method.
(4) The Company historically has not paid dividends.
(5) Grant price is the closing price of the Company's common stock on the date of grant.


	Shares	Weighted-average exercise price	Weighted-average remaining contractual term	Aggregate intrinsic value*
Outstanding at December 29, 2012	2,689	$ 34.43	2.9	$ 5,136
Granted	175	53.83
Exercised	(939)	32.20
Canceled	(98)	35.87
Expired	-	-

Outstanding at December 28, 2013	1,827	$ 37.37	2.6	$ 74,160

Exercisable at December 28, 2013	540	$ 35.73	1.8	$ 22,678

* Aggregate intrinsic value is defined as the difference between the current market value at the reporting
date (the closing price of the Company's common stock on the last trading day of the period) and the
exercise price of awards that were in-the-money. The closing price of the Company's common stock at
December 29, 2012 and December 28, 2013, was $31.60 and $77.72, respectively.